Therefore, addition, of the biomarkers TNFα and ST2/IL-33R, to know risk factors for NAFLD/NASH, would allow clinicians to both identify patients at potential risk of disease progression and monitor any therapeutic intervention. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatohepatitis.